Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RIPK1 | Q13546 | 5/20 | 0.40 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.38 |
| ▸ | FFAR2 | O15552 | 2/20 | 0.36 |
| ▸ | POLB | P06746 | 2/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.35 |
| ▸ | MEN1 | O00255 | 2/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.35 |
| ▸ | GAA | P10253 | 2/20 | 0.34 |
| ▸ | RAB9A | P51151 | 1/20 | 0.34 |
| ▸ | LMNA | P02545 | 1/20 | 0.33 |
| ▸ | TSHR | P16473 | 2/20 | 0.33 |
| ▸ | HTT | P42858 | 1/20 | 0.33 |
| ▸ | ACE | P12821 | 2/20 | 0.32 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13091648 | 1.00 | RIPK1 (0.40) | RIPK1HSD17B10FFAR2POLBALDH1A1 | |
| SCHEMBL13101399 | 0.81 | HSD17B10 (0.54) | RIPK1HSD17B10FFAR2POLBALDH1A1 | |
| SCHEMBL13091650 | 0.81 | HSD17B10 (0.54) | RIPK1HSD17B10FFAR2POLBALDH1A1 | |
| SCHEMBL13091670 | 0.81 | ABCB1 (0.43) | RIPK1HSD17B10FFAR2POLBALDH1A1 | |
| SCHEMBL13091641 | 0.81 | ABCB1 (0.43) | RIPK1HSD17B10FFAR2POLBALDH1A1 | |
| SCHEMBL13091660 | 0.81 | ABCB1 (0.43) | RIPK1HSD17B10FFAR2POLBALDH1A1 | |
| SCHEMBL13091649 | 0.80 | RIPK1 (0.41) | RIPK1HSD17B10FFAR2POLBALDH1A1 | |
| SCHEMBL13101400 | 0.80 | RIPK1 (0.41) | RIPK1HSD17B10FFAR2POLBALDH1A1 | |
| SCHEMBL13101397 | 0.76 | GAA (0.37) | FFAR2POLBALDH1A1MEN1KMT2A | |
| SCHEMBL13091645 | 0.76 | GAA (0.37) | FFAR2POLBALDH1A1MEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100266675-A1 | LIPOPROTEINS, LIPOPEPTIDES AND ANALOGS, AND METHODS FOR MAKING AND USING THEM | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2010-10-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100266675-A1 | LIPOPROTEINS, LIPOPEPTIDES AND ANALOGS, AND METHODS FOR MAKING AND USING THEM | LIPG, VEGFA, LIPE | RIPK1 2547/4885HSD17B10 1842/4885FFAR2 1040/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.